IL-37 Suppresses CNS Autoimmunity by Increasing the Frequency of Treg Cells and Reducing CD4 + T Cell-Derived IL-10 Production.

Reza Yazdani,Hamed Naziri,Gholamreza Azizi,Bogoljub Ciric,Mozhde Askari,Amir Moghadam Ahmadi,Jaya Aseervatham,Guang-Xian Zhang,Abdolmohamad Rostami
DOI: https://doi.org/10.1186/s12974-024-03295-1
IF: 9.3
2024-01-01
Journal of Neuroinflammation
Abstract:Interleukin-37 (IL-37) has anti-inflammatory properties in innate and adaptive immunity. Patients with multiple sclerosis (MS), an autoimmune inflammatory demyelinating disease of the central nervous system (CNS), have increased serum levels of IL-37. However, it is unknown whether IL-37 has an inhibitory effect on ongoing autoimmune neuroinflammation, thus offering a potential MS therapy. Here, we examined the effect of IL-37 in an experimental autoimmune encephalomyelitis (EAE) model after disease onset to determine if it was protective. IL-37-treated mice developed a less severe disease than control mice, with reduced demyelination as determined by increased expression of myelin basic protein. IL-37 suppressed inflammation by decreasing infiltration of CD4 + T cells into the CNS and increasing the frequency of regulatory T cells, while IL-10 expression by CD4 + T cells decreased over time in the CNS. Our findings confirm the immunomodulatory role of IL-37 in CNS inflammation during ongoing disease, thus indicating the potential of IL-37 as an inhibitory reagent for MS therapy.
What problem does this paper attempt to address?